Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Giorgio Valabrega, Matthew A. Powell, Sakari Hietanen, Eirwen M. Miller, Zoltan Novak, Robert Holloway, Dominik Denschlag, Tashanna Myers, Anna M. Thijs, Kathryn P. Pennington, Lucy Gilbert, Evelyn Fleming, Oleksandr Zub, Lisa M. Landrum, Beyhan Ataseven, Radhika Gogoi, Iwona Podzielinski, Noelle Cloven, Bradley J. Monk, Sudarshan SharmaThomas J. Herzog, Ashley Stuckey, Bhavana Pothuri, Angeles Alvarez Secord, Dana Chase, Veena Vincent, Oren Meyers, Jamie Garside, Mansoor Raza Mirza, Destin Black
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial'. Together they form a unique fingerprint.